Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ALEC | 8-K | neutral | 3/10 | Alector's board approved an option repricing on October 13, 2026, lowering the exercise price of approximately 4.05 mill | Oct 14, 2026 |
| APVO | 8-K | neutral | 3/10 | Aptevo announced a non-clinical scientific presentation of its multispecific CD40-directed platform at the SITC 2026 Ann | Oct 14, 2026 |
| PLSE | 8-K | neutral | 4/10 | Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center at the Hospital for En | Oct 14, 2026 |
| VIR | 8-K | bullish | 6/10 | Vir Biotechnology entered into a collaboration and license agreement with Gilead Sciences to discover and engineer three | Oct 14, 2026 |
| COYA | 8-K | mixed | 5/10 | Coya Therapeutics announced plans to initiate an open-label extension (OLE) of its Phase 2/3 ALSTARS trial for COYA 302 | Oct 14, 2026 |
| MXCT | 8-K | bullish | 6/10 | MaxCyte reported preliminary Q3 2026 core revenue of ~$8.1M (+26% YoY) and raised full-year 2026 revenue guidance to ~$3 | Oct 14, 2026 |
| ONMD | 8-K | bullish | 5/10 | OneMedNet received written notice from Nasdaq on October 13, 2026 confirming it has regained compliance with the $1.00 m | Oct 14, 2026 |
| AKBA | 8-K | neutral | 3/10 | Akebia Therapeutics disclosed the resignation of Nicholas Grund, Senior Vice President and Chief Commercial Officer, eff | Oct 14, 2026 |
| TRDA | 8-K | bullish | 6/10 | Entrada Therapeutics announced positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-45-201 study of ENTR-601-45 | Oct 14, 2026 |
| KPTI | 8-K | neutral | 3/10 | Karyopharm Therapeutics filed an 8-K to extend the forbearance period under its existing Forbearance Agreement and Limit | Oct 14, 2026 |
| AQST | 8-K | bullish | 6/10 | Aquestive Therapeutics granted Eton Pharmaceuticals exclusive U.S. rights to commercialize LIBERVANT (diazepam) buccal f | Oct 14, 2026 |
| ETON | 8-K | bullish | 6/10 | Eton Pharmaceuticals entered into an exclusive U.S. license and supply agreement with Aquestive Therapeutics for LIBERVA | Oct 14, 2026 |
| XERS | 8-K | neutral | 3/10 | Xeris Biopharma filed patent infringement lawsuits against Torrent Pharma, Cycle Pharmaceuticals, Rising Pharma, and rel | Oct 14, 2026 |
| UTHR | 8-K | bullish | 7/10 | United Therapeutics (UTHR) entered into a comprehensive settlement agreement with Liquidia Technologies, resolving all p | Oct 14, 2026 |
| QNRX | 8-K | bullish | 5/10 | Quoin Pharmaceuticals announced that its lead product candidate QRX003 received Orphan Drug Designation from the EMA for | Oct 14, 2026 |
| VSTM | 8-K | bullish | 7/10 | Verastem reported preliminary Q3 2026 net product revenue of ~$23.9-24.1M (vs $11.2M YoY), announced CEO Dan Paterson's | Oct 14, 2026 |
| LQDA | 8-K | mixed | 7/10 | Liquidia entered into a global settlement with United Therapeutics (UTC) resolving all six pending lawsuits, including p | Oct 13, 2026 |
| BMEA | 8-K | bullish | 6/10 | Biomea Fusion reported Phase 1 topline data for BMF-650, its next-generation oral GLP-1 receptor agonist for obesity. In | Oct 13, 2026 |
| RVMD | 8-K | bullish | 6/10 | Revolution Medicines triggered a $250M Tranche A loan draw from Royalty Pharma upon FDA approval of RASONQUE (daraxonras | Oct 13, 2026 |
| SNTI | 8-K | bearish | 5/10 | Senti Biosciences adjourned its 2026 Annual Meeting of Stockholders without conducting any business, despite a quorum be | Oct 13, 2026 |
| MRK | 8-K | neutral | 2/10 | Merck announced the election of Paul J. Diaz to its Board of Directors, effective November 1, 2026. Mr. Diaz, a managing | Oct 13, 2026 |
| TCRT | 8-K | bullish | 8/10 | Alaunos Therapeutics (TCRT) has entered into a definitive merger agreement to acquire Velaris Therapeutics in a reverse | Oct 13, 2026 |
| BIAF | 8-K | neutral | 3/10 | bioAffinity Technologies filed an 8-K announcing a poster presentation at CHEST 2026 on its investigational sputum-based | Oct 13, 2026 |
| APUS | 8-K | neutral | 4/10 | Apimeds Pharmaceuticals US, Inc. (APUS) announced via its wholly owned subsidiary MindWave Innovations Inc. that it has | Oct 13, 2026 |
| OTLC | 8-K | neutral | 2/10 | Oncotelic Therapeutics filed an 8-K to report presentations at Drug Discovery 2026 regarding its PDAOAI platform and hep | Oct 13, 2026 |
| PHIO | 8-K | neutral | 3/10 | Phio Pharmaceuticals announced the successful completion of its first commercial-scale cGMP batch of PH-762 drug substan | Oct 13, 2026 |
| CRVO | 8-K | bullish | 6/10 | CervoMed reported initial 12-week biomarker data from its Phase 2a trial of neflamapimod in nfvPPA, showing a mean reduc | Oct 13, 2026 |
| SABS | 8-K | bullish | 6/10 | SAB Biotherapeutics announced FDA Fast Track designation for SAB-142, its disease-modifying immunotherapy for Stage 3 ty | Oct 13, 2026 |
| MTVA | 8-K | neutral | 3/10 | MetaVia Inc. appointed Sarah Kaplan Browne, M.D. as Chief Medical Officer, effective October 12, 2026. Dr. Browne brings | Oct 13, 2026 |
| TRAX | 8-K | bullish | 7/10 | First Tracks Biotherapeutics announced positive top-line results from Cohort 1 of ANB033's Phase 1b gluten-challenge tri | Oct 13, 2026 |